Unknown

Dataset Information

0

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.


ABSTRACT:

Introduction

The PACS01 trial has demonstrated that a docetaxel addition to adjuvant anthracycline-based chemotherapy improves disease-free survival (DFS) and overall survival of node-positive early breast cancer (EBC). We searched for prognostic and predictive markers for docetaxel's benefit.

Methods

Tumor samples from 1,099 recruited women were analyzed for the expression of 34 selected proteins using immunohistochemistry. The prognostic and predictive values of each marker and four molecular subtypes (luminal A, luminal B, HER2-overexpressing, and triple-negative) were tested.

Results

Progesterone receptor-negativity (HR = 0.66; 95% CI 0.47 to 0.92, P = 0.013), and Ki67-positivity (HR = 1.53; 95% CI 1.12 to 2.08, P = 0.007) were independent adverse prognostic factors. Out of the 34 proteins, only Ki67-positivity was associated with DFS improvement with docetaxel addition (adjusted HR = 0.51, 95% CI 0.33 to 0.79 for Ki67-positive versus HR = 1.10, 95% CI 0.75 to 1.61 for Ki67-negative tumors, P for interaction = 0.012). Molecular subtyping predicted the docetaxel benefit, but without providing additional information to Ki67 status. The luminal A subtype did not benefit from docetaxel (HR = 1.16, 95% CI 0.73 to 1.84); the reduction in the relapse risk was 53% (HR = 0.47, 95% CI 0.22 to 1.01), 34% (HR = 0.66, 95% CI 0.37 to 1.19), and 12% (HR = 0.88, 95% CI 0.49 to 1.57) in the luminal B, HER2-overexpressing, and triple-negative subtypes, respectively.

Conclusions

In patients with node-positive EBC receiving adjuvant anthracycline-based chemotherapy, the most powerful predictor of docetaxel benefit is Ki67-positivity.

SUBMITTER: Jacquemier J 

PROVIDER: S-EPMC3326551 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.

Jacquemier Jocelyne J   Boher Jean-Marie JM   Roche Henri H   Esterni Benjamin B   Serin Daniel D   Kerbrat Pierre P   Andre Fabrice F   Finetti Pascal P   Charafe-Jauffret Emmanuelle E   Martin Anne-Laure AL   Campone Mario M   Viens Patrice P   Birnbaum Daniel D   Penault-Llorca Frédérique F   Bertucci François F  

Breast cancer research : BCR 20111101 6


<h4>Introduction</h4>The PACS01 trial has demonstrated that a docetaxel addition to adjuvant anthracycline-based chemotherapy improves disease-free survival (DFS) and overall survival of node-positive early breast cancer (EBC). We searched for prognostic and predictive markers for docetaxel's benefit.<h4>Methods</h4>Tumor samples from 1,099 recruited women were analyzed for the expression of 34 selected proteins using immunohistochemistry. The prognostic and predictive values of each marker and  ...[more]

Similar Datasets

| S-EPMC4336178 | biostudies-literature
| S-EPMC7790855 | biostudies-literature
| S-EPMC4927915 | biostudies-other
| S-EPMC8756114 | biostudies-literature
| S-EPMC9096864 | biostudies-literature
| S-EPMC2917014 | biostudies-literature
| S-EPMC6069924 | biostudies-other
| S-EPMC9968597 | biostudies-literature
| S-EPMC8828517 | biostudies-literature
| S-EPMC2903333 | biostudies-literature